

individual interviews will respond to more personal questions. The semistructured individual interviews will explore behavioral, social, and economic conditions that might

contribute to risk for HIV infection. The focus groups and interviews will each take about two hours each to complete. A screening interview for women participants will take about 11 minutes

to complete. A demographic information form will take all participants an additional five minutes to complete. The total estimated annual burden to the public is 202 hours.

ESTIMATE OF ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
African American Women Ages 18–29 Years.	Screening Form	55	1	8/60
	Contact Form	55	1	3/60
	Demographic Information Form	32	1	5/60
	Focus Group Guide	32	1	115/60
	Individual Interview	32	1	2
Community Leaders	Focus Group Guide (CL)	32	1	115/60
	Demographic Information Form (CL)	32	1	5/60

Dated: May 30, 2007.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and Prevention.
 [FR Doc. E7–11088 Filed 6–7–07; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Studies of the Effects of Influenza Antiviral Agents, Funding Opportunity Announcement (FOA) IP07–003, and Epidemiology of Influenza in Tropical Developing Countries, FOA IP07–004

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting of the aforementioned Special Emphasis Panel.

Time and Date: 12 p.m.–4 p.m., July 10, 2007 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of research grant applications in response to FOA IP07–003, “Studies of the Effects of Influenza Antiviral Agents,” and FOA IP–07–004

“Epidemiology of Influenza in Tropical, Developing Countries.”

CONTACT PERSON FOR MORE INFORMATION: Trudy Messmer, PhD, Scientific Review Administrator, 1600 Clifton Road, Mailstop C–19, Atlanta, GA 30333, telephone (404) 639–3770.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 1, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.
 [FR Doc. E7–11100 Filed 6–7–07; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Council for the Elimination of Tuberculosis Meeting (ACET) In Accordance With Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) Announces the Following Council Meeting of the Aforementioned Committee

Times and Dates:
 8:30 a.m.–5:15 p.m., July 10, 2007.
 8:30 a.m.–12:30 p.m., July 11, 2007.
Place: Corporate Square, Building 8, 1st Floor Conference Room, Atlanta, Georgia 30333, telephone (404)639–8317.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: This council advises and makes recommendations to the Secretary, Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the elimination of tuberculosis. Specifically, the Council makes recommendations regarding policies, strategies, objectives, and priorities; addresses the development and application of new technologies; and reviews the extent to which progress has been made toward eliminating tuberculosis.

Matters to be Discussed: Agenda items include issues pertaining to Tuberculosis and Immigration, Extensively Drug Resistant Tuberculosis Preparedness Planning; and Special Issues in Extensively Drug Resistant Tuberculosis Surveillance and Control and other related tuberculosis issues. Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Margie Scott-Cseh, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 1600 Clifton Road, NE, M/S E–07, Atlanta, Georgia 30333, telephone (404)639–8317.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: June 1, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.
 [FR Doc. E7–11089 Filed 6–7–07; 8:45 am]
BILLING CODE 4163–18–P